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Edited by Veli-Pekka LehtoAbstract 4-Methylumbelliferone (MU) inhibits the cell surface
hyaluronan (HA) formation, and that such inhibition results in
suppression of adhesion and locomotion of cultured melanoma
cells. Here, we examine the eﬀect of MU on melanoma cell
metastasis in vivo. MU-treated melanoma cells showed both de-
creased cell surface HA formation and suppression of liver
metastasis after injection into the mice. Oral administration of
MU to mice decreased tissue HA content. These HA knock-
down mice displayed suppressed liver metastasis. Thus, both cell
surface HA of melanoma cells and recipient liver HA can pro-
mote liver metastasis, indicating that MU has potential as an
anti-metastatic agent.
 2005 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Metastasis, a clinical and histological feature of malignant
tumor cells, is initiated by detachment of tumor cells from
the primary lesion. These cells enter the vascular system and
ﬁnally become established in remote tissues [1]. Metastasis
worsens the clinical prognosis of the patient and, in spite of
improvements in therapeutic methods such as surgery, radio-
therapy, chemotherapy and immunotherapy, frequently results
in death from cancer. Therefore, blockade of metastasis is an
important strategy to increase the survival of patients with
malignant tumors and the development of more eﬀective
anti-metastatic agents is required [2].
Hyaluronan (HA) is a non-sulfated glycosaminoglycan
(GAG) of high molecular mass that consists of repeated b-
1,4-GlcUA-b-1,3-GlcNAc disaccharide units. It is well estab-
lished that HA participates in various phases of the metastasis
of malignant tumors [3–5]. HA-rich matrices surroundingAbbreviations: HA, Hyaluronan; MU, 4-methylumbelliferone; GAG,
glycosaminoglycan; FCS, fetal calf serum; HAS, hyaluronan synthase;
PBS, phosphate-buﬀered saline; UGT, UDP-glucuronosyltransferase
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to a worse clinical prognosis [6–8]. Indeed, the metastatic po-
tency of malignant tumor cells is enhanced by transfection
with the gene coding for HA synthase (HAS), an HA-synthe-
sizing enzyme [6,9,10]. Conversely, inhibiting HAS expression
in tumor cells with an antisense HAS construct reduces cell
adhesion [11,12]. Thus, HA is a risk factor for metastasis of
malignant tumors, suggesting that metastasis could be sup-
pressed by inhibition of HA production.
We have reported that 4-methylumbelliferone (MU) inhibits
HA synthesis in human dermal ﬁbroblasts [13–15]. Together,
these results suggest that MU, as a suppressor of HAS activity,
may have an inhibitory eﬀect on the metastasis of malignant
tumor cells. Consequently, we recently examined the eﬀect of
MU on the adhesion and locomotion of malignant tumor cells,
which are important properties during the early stages of
metastasis. We demonstrated that HA enhances both the adhe-
sion and the locomotion of B16F-10 melanoma cells, a highly
malignant tumor cell line, and that these increases are inhibited
by MU [16].
In the present study, we examined whether MU inhibits the
metastasis of melanoma cells to mouse tissues in vivo. We here
report that MU has an inhibitory eﬀect on the liver metastasis
of B16F-10 melanoma cells and therefore shows potential as
an anti-metastatic agent.2. Materials and methods
2.1. Materials
MU and umbelliferone (UM) were purchased from Sigma Chemical
Co. (St. Louis, MO) and actinase E was obtained from Kaken Phar-
maceutical Co. (Tokyo, Japan). HA and Streptomyces hyaluronidase
were purchased from Seikagaku Co. (Tokyo, Japan). All other re-
agents were of analytical grade and obtained from commercial sources.
2.2. Tumor cells
B16F-10 melanoma cells (henceforth referred to as melanoma cells)
were maintained in RPMI-1640 (Nissui, Tokyo, Japan) supplemented
with 10% fetal calf serum (FCS), L-glutamine and antibiotics. Addition
of MU to the medium was carried out as described previously [13].
2.3. Mice
Ten-week-old female C57BL/6 mice (19–22 g body weight) were
used throughout the experiments. All mice were purchased from Japan
Clea (Tokyo, Japan) and housed in conventional conditions with water
and food ad libitum. MU was suspended in 1% arabic gum at a densityblished by Elsevier B.V. All rights reserved.
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mouse. Mice were placed under light diethyl ether anesthesia and
blood samples were taken by cardiac puncture, then the total liver
was removed. All animal experiments were performed according to
the Guidelines for Animal Experimentation of Hirosaki University.2.4. Assay of blood MU
The concentration of blood MU was assayed by using HPLC [17].
Brieﬂy, the internal standard (30 ll of a 50 lg/ml solution of UM in
methanol) was added to 100 ll of a whole blood sample. After mixing
the blood sample with 1.0 ml of ethyl acetate, the mixture was centri-
fuged at 2000 · g for 10 min. The ethyl acetate layer was removed,
evaporated to dryness under air and reconstituted in 500 ll of metha-
nol. The methanol solution was centrifuged at 4000 · g for 10 min and
200 ll of injection sample was obtained. The HPLC system consisted
of an L-6200 liquid chromatograph, L-7200 autosampler, F-1050 ﬂuo-
rescence spectrophotometer and D-7500 integrator (Hitachi Co., To-
kyo, Japan). Reverse phase chromatography was carried out on a
TSK-GEL ODS-120T column (0.46 cm · 25.0 cm; Tosoh Co., Tokyo,
Japan) with a mobile phase of 40% methanol in water at a ﬂow rate of
0.5 ml/min. The column temperature for this HPLC procedure was
35 C and detection was performed at excitation and emission wave-
lengths of 350 and 450 nm, respectively.2.5. Assay of GAG in mouse liver
Liver samples (0.95–1.1 g wet weight) were washed gently with cold
isotonic saline, sliced with scissors and homogenized in 2 volumes of
saline at 0 C. The homogenate was centrifuged and the pellet was del-
ipidated as described previously [18], then dried with diethyl ether and
weighed to obtain the dry weight. The dry liver was incubated with
actinase E (0.1 mg/mg of dry weight) and GAG in the liver was ana-
lyzed by HPLC as described previously [16].2.6. Assay of liver metastasis
On the day of inoculation, melanoma cells were harvested from the
cultures and washed twice in culture medium. Cells suspended at a
density of 1 · 106 cells in 0.05 ml of PBS were injected into the lateral
tail vein. To investigate the eﬀect of cell surface HA, cells pre-incu-
bated with 0.5 mM MU for 48 h were inoculated. To determine the
role of liver HA, mice were administered MU for 2 weeks and inocu-
lated with melanoma cells untreated with MU. Controls were injected
with cells untreated with MU and administered 1% arabic gum. At 14
days after the injection of melanoma cells, the liver was removed and
surface colonies were counted under the dissecting microscope.Fig. 1. Eﬀect of MU on HA synthesis by liver. Mice were administered
MU, and the concentration of MU in blood (A) and the HA content of
liver (B) were determined by HPLC as described in Section 2. In some
experiments, MU was administered to mice every 12 h for 5 days, and
the HA content of liver was determined (C). Each point is the mean for
10 animals ±S.D. The grouped data in B were analyzed for signiﬁcance
in comparison with the control group by using the Mann–Whitney
test; *P < 0.05.3. Results and discussion
3.1. Eﬀect of MU on HA synthesis by mouse liver
In order to investigate the eﬀect of MU on HA synthesis in
mouse tissues, MU suspended in 1% arabic gum was adminis-
tered orally at a dose of 3 mg/g body weight, and its kinetics
and dynamics were studied. The concentration of MU in whole
blood was analyzed by HPLC as described in Section 2. As
shown in Fig. 1A, the concentration of MU was highest at
3 h after administration and then decreased quickly. MU could
not be detected at 24 h.
Next, we also investigated the eﬀect of MU on the HA con-
tent of various tissues, including liver, skin, lung and brain. As
shown in Fig. 1B, the HA content of liver tissue decreased after
administration of MU (Fig. 1B), whereas no signiﬁcant de-
crease was observed in other tissues (data not shown). The li-
ver content of HA decreased in a time-dependent manner,
showing a signiﬁcant decrease at 6, 9 and 12 h after adminis-
tration, but was restored at 24 h. These observations suggest
that liver HA can be suppressed continually by administration
of MU every 12 h. Therefore, mice were given MU every 12 hto maintain HA knock-down conditions. Under these condi-
tions, the liver content of HA was suppressed continually by
31.8% compared with that in mice not given MU (Fig. 1C).
We also investigated whether MU inhibits the synthesis of
other GAGs such as chondroitin sulfate, dermatan sulfate,
and heparin sulfate in mice liver. The signiﬁcant inhibition of
MU on the synthesis of these GAGs was not observed (data
Fig. 2. Eﬀect of MU on the formation of metastatic nodules on the
liver. Each mouse was inoculated with melanoma cells (1 · 106 cells)
via the tail vein. Treatment of the control group, the cells treated with
MU group and the mice treated with MU group is described in Section
2. After 14 days, the metastatic colonies were counted under a
dissecting microscope (A). Each bar is the mean for 10 animals per
group +S.D. Grouped data were analyzed for signiﬁcance in compar-
ison with the control group by using the Mann–Whitney test;
*P < 0.05. Metastatic colonies on the liver can be observed as black
spheroids (B).
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HA synthesis in mice liver.
3.2. Eﬀect of HA on metastasis
To examine the eﬀect of MU-mediated inhibition of cell sur-
face HA formation on liver metastasis of melanoma cells in
vivo, cells were treated with 0.5 mM of MU for 48 h and sub-
sequently injected into the tail vein of mice. The HA content of
injected melanoma cells was decreased by MU treatment (by
32%, 5.2 pmol/104 cells) (data not shown), which were in agree-
ment with the data published by Kudo et al. [16]. After 14
days, mice were killed and metastatic nodules were counted.
As shown in Fig. 2, many metastatic nodules, appearing as
black spheroids, were observed on the liver surface of mice in-
jected with control melanoma cells without MU treatment. On
the other hand, the number of metastatic nodules was mark-
edly decreased (by 64%) in mice injected with melanoma cells
treated with MU. Similar results were observed on the surface
of lung, kidney, spleen, and mesentery (data not shown). Col-lectively, these results suggest that the formation of cell surface
HA is necessary for metastasis of melanoma cells.
As mentioned above, oral admistration of MU selectively
inhibits the HA synthesis in liver tissue (Fig. 1B), whereas no
signiﬁcant inhibitory eﬀect was observed in other tissues.
Therefore, we examined the eﬀect of recipient HA synthesized
by liver cells on the metastasis of melanoma cells. Melanoma
cells untreated with MU were injected into the tail vein of
mice, and subsequently MU was administered twice daily for
14 days to maintain HA knock-down conditions in the liver.
As shown in Fig. 2, oral administration of MU reduced the
number of metastatic nodules in liver tissue by 32%. Thus, re-
cipient HA synthesized by the liver is also crucial for liver
metastasis of melanoma cells, suggesting that it might be a
scaﬀold for, rather than a barrier against, metastasizing mela-
noma cells.
Our previous studies have shown that MU-mediated inhibi-
tion of formation of cell surface HA by melanoma cells re-
sults in suppression of their adhesion and locomotion [16].
On the contrary, HA, which is released from the cell surface
and ﬁnally forms an HA-rich matrix, increased the adhesion
and locomotion of melanoma cells [16], suggesting that HA
is crucial for promoting the metastasis of melanoma cells in
vitro.
In this study, we examined the eﬀect of MU-mediated inhi-
bition of HA synthesis by melanoma cells on their ability to
form liver metastases in vivo. Furthermore, we investigated
the eﬀect of modulating the liver content of HA in the recipient
mice on the formation of liver metastases by melanoma cells.
Firstly, we demonstrated that HA synthesis in mouse liver is
inhibited by oral administration of MU. The inhibitory eﬀect
of MU was observed only in the liver, and no clear inhibition
was detected in other tissues. Several studies have reported
that liver appears to be the main organ for MU metabolism
[19,20]. Therefore, accumulation of a large amount of MU
may speciﬁcally reduce HA synthesis by liver cells. MU selec-
tively inhibited HA synthesis, whereas other GAGs such as
chondroitin sulfate, dermatan sulfate, and heparin sulfate were
not inﬂuenced by administration of MU. Recently, Kakizaki et
al. [15] demonstrated that MU inhibits the HA synthesis
involving the glucuronidation of MU by endogenous UDP-
glucuronosyltransferase (UGT) resulting in a depletion of
UDP-GlcUA. They considered two possible molecular mecha-
nisms related to the selective inhibition of the synthesis by MU
[15]. They supposed that MU speciﬁcally targets HAS due to
its cellular localization, which is diﬀerent from other glyco-
syltransferases, exostosin family and chondroitin synthases in-
volved in the synthesis of heparan sulfate and chondroitin
sulfate, respectively. Indeed, all the GAGs, with the single
exception of HA, are synthesized at the intracellular Golgi net-
work, whereas HA is synthesized on the inner side of the plas-
ma membrane by a membrane-associated HAS. Another
explanation for the selective inhibition would be the preferen-
tial eﬀects of MU on the chain elongation of a large molecular
mass of HA.
Secondly, the inhibitory eﬀect of MU on cell surface HA for-
mation led to suppression of liver metastasis by melanoma
cells. Cell surface HA synthesized by HAS is secreted into,
and ﬁnally forms, the extracellular matrix [21] and therefore
is at the front line during intercellular interactions. It is well
established that HA-rich matrices surrounding malignant
tumor cells indicate a worse prognosis because of higher
S. Yoshihara et al. / FEBS Letters 579 (2005) 2722–2726 2725metastatic potency [7,8]. Indeed, some types of malignant tu-
mor cells, such as mesothelioma and Wilms tumor, produce
large amounts of HA, and HA overproduction by tumor cells
enhances their metastatic potential [6]. Moreover, introduction
of the HAS gene into malignant tumors also enhances their
metastatic potential [6,9,10], whereas inhibition of HAS
expression in tumor cells by introduction of antisense HAS
diminishes it [11,12]. Taken together with these ﬁndings and
our previous observation that MU inhibits the adhesion and
locomotion of cultured melanoma cells [16], the present study
strongly suggests that inhibition of cell surface HA synthesis
may inhibit the metastasis of melanoma cells, and that HA-
rich matrices surrounding melanoma cells provide a suitable
environment for metastasis.
The role of recipient HA in the remote tissues into which
malignant tumor cells invade is unclear, except that our previ-
ous studies demonstrated that the cell adhesion and locomo-
tion of cultured melanoma cells were enhanced by exogenous
HA [16]. Therefore, thirdly, we investigated the eﬀect of recipi-
ent HA on liver metastasis of melanoma cells by using HA
knock-down mice generated by oral administration of MU.
We demonstrated that recipient liver HA promotes the liver
metastasis of melanoma cells, suggesting that recipient HA
works as a scaﬀold to accelerate metastasis.
Recently, Camenisch et al. [22] produced genetically knock-
out mice lacking the HAS-2 gene and reported that these ani-
mals underwent fetal death due to disordered development of
the cardiovascular system. This observation underlines the dif-
ﬁculty in obtaining animals that have suppressed HA levels in
tissues, and suggests that MU may be a useful tool for the
examination of the functions of HA. Although several studies
have shown that the metastatic potency of tumor cells is en-
hanced by transfection with the gene for HAS [6,23], we have
adopted the opposite approach by using the inhibitor MU to
demonstrate that both the formation of cell surface HA and
the synthesis of host liver HA are necessary for liver metastasis
by melanoma cells. Thus, this study is the ﬁrst demonstration
of MU-mediated inhibition of liver metastasis by melanoma
cells in vivo.
In summary, by using HA knock-down mice treated with
MU, we have demonstrated that the metastasis of melanoma
cells is enhanced both by cell surface HA on the tumor cells
and by recipient HA in the liver. Our results strongly indicate
that MU has potential as a novel anti-metastatic agent to inhi-
bit the metastasis of melanoma cells.
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